Drugs / HY05350
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07083323 | Jul 2025 → Mar 2028 expected | neoplasm | Sichuan Huiyu Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HY05350 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07083323 ↗ |
| Route | Intravenous | “administered intravenously” NCT07083323 ↗ |